SXTPNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SXTPW
60 DEGREES PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.83−0.03 (-3.29%)
Close on Oct 19, 2026
- Market cap
- $2.20M
- P/E (TTM)
- –
- Dividend yield
- –
60 Degrees Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | 60 Degrees Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $2.91M | $164.85M |
| Enterprise Value | $1.80M | $87.06M |
| PS Ratio | 2.62 | 3.60 |
| PB Ratio | 1.11 | 2.03 |
| P/TBV Ratio | 1.26 | 2.31 |
Enterprise value
| Measure | 60 Degrees Pharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | 1.62 | 2.43 |
Income (trailing twelve months)
| Measure | 60 Degrees Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $1.11M | $57.94M |
| Gross Profit | $215.79K | $90.47M |
| Operating Income | -$8.61M | -$21.44M |
| Pretax Income | -$8.11M | -$14.45M |
| Net Income | -$8.11M | -$22.46M |
| EBITDA | -$8.55M | -$16.91M |
Margins
| Measure | 60 Degrees Pharmaceuticals | Industry median |
|---|---|---|
| Gross Margin | 19.4% | 52.3% |
| Operating Margin | -774.9% | -44.5% |
| Pretax Margin | -730.3% | -13.0% |
| Profit Margin | -729.9% | -39.2% |
| EBITDA Margin | -769.4% | -31.3% |
| FCF Margin | -800.6% | -8.85% |
Returns
| Measure | 60 Degrees Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | -321.6% | -53.1% |
| Return on Assets (ROA) | -191.6% | -41.0% |
| Return on Invested Capital (ROIC) | -659.1% | -32.0% |
| Return on Capital Employed (ROCE) | -321.5% | -37.8% |
Growth
| Measure | 60 Degrees Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 73.2% | 6.01% |
| Revenue Growth (3Y CAGR) | 65.2% | 2.25% |
Balance sheet
| Measure | 60 Degrees Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $1.02M | $62.42M |
| Total Debt | $2.00K | $120.13M |
| Net Cash (Debt) | $1.02M | $15.68M |
| Net Cash Per Share | $0.29 | $0.66 |
| Equity (Book Value) | $2.61M | $48.79M |
| Book Value Per Share | $0.74 | $1.36 |
| Tangible Book Value | $2.31M | $23.06M |
| Working Capital | $2.13M | $75.77M |
Financial position
| Measure | 60 Degrees Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 2.32 | 3.30 |
| Quick Ratio | 0.99 | 2.39 |
| Debt / Equity | 0.00 | 0.51 |
| Interest Coverage | -1134.85 | -7.12 |
Cash flow (trailing twelve months)
| Measure | 60 Degrees Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$8.77M | -$12.35M |
| Capital Expenditures | -$119.88K | -$1.06M |
| Free Cash Flow | -$8.89M | -$20.28M |
| FCF Per Share | -$2.53 | -$0.42 |
Efficiency
| Measure | 60 Degrees Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 0.26 | 0.38 |
| Inventory Turnover | 1.07 | 2.67 |
| Revenue Per Employee | $370.33K | $398.96K |
| Profits Per Employee | -$2.70M | -$703.34K |
| Employee Count | 3 | 74 |
Dividends and yields
| Measure | 60 Degrees Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -278.7% | -22.7% |
| FCF Yield | -305.7% | -9.07% |
Shares
| Measure | 60 Degrees Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 3,516,990 | 58,179,650 |
| Shares Change (QoQ) | 0.85% | 0.54% |
| Float | 2,778,380 | 49,173,100 |
| Shares Held by Insiders | 21.0% | 11.6% |
| Shares Held by Institutions | 21.5% | 59.4% |
Scores
| Measure | 60 Degrees Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | -21.86 | -0.24 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from 60 Degrees Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.